Company · CIK 0001432732 · SIC 3841 — Surgical & Medical Instruments & Apparatus
TriVascular Technologies, Inc. · TRIV
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2016 DUForm 4 → | Feb 5, 2:04 pm EST | Douglas A RoederDirector, 10% Owner | 3,536,059 | — | — | 0 | — | plan? |
| Feb 3, 2016 UForm 4 → | Feb 5, 2:04 pm EST | Delphi Management Partners VIII, L.L.C. +910% Owner | 3,535,910 | — | — | 0 | — | plan? |
| Feb 3, 2016 DFMForm 4 → | Feb 4, 4:45 pm EST | Robert ThomasDirector | 123,162 | $3.39 | $80,306 | 0 | — | plan? |
| Feb 3, 2016 DFMForm 4 → | Feb 4, 4:43 pm EST | Daniel Jeffrey MooreDirector | 31,322 | $3.39 | $76,115 | 0 | — | plan? |
| Feb 3, 2016 DFMForm 4 → | Feb 4, 4:42 pm EST | Shari L O'QuinnVP Clinical/Regulatory Affairs | 102,476 | $3.52 | $223,289 | 0 | — | plan? |
| Feb 3, 2016 DFMForm 4 → | Feb 4, 4:41 pm EST | Vivek K JayaramanVP Global Sales and Marketing | 126,626 | $3.56 | $262,929 | 0 | — | plan? |
| Feb 3, 2016 DForm 4 → | Feb 4, 4:41 pm EST | New Enterprise Associates 12, Limited Partnership +810% Owner | 3,943,269 | — | — | 0 | — | plan? |
| Feb 3, 2016 DFMForm 4 → | Feb 4, 4:40 pm EST | Kimberley A. EltingVP, Gen. Counsel and Secretary | 157,361 | $4.19 | $428,064 | 0 | — | plan? |
| Feb 3, 2016 DFMForm 4 → | Feb 4, 4:37 pm EST | Michael V. ChobotovChief Technology Officer | 243,161 | $3.96 | $169,014 | 0 | — | plan? |
| Feb 3, 2016 DFMForm 4 → | Feb 4, 4:36 pm EST | Christopher G. ChavezPresident, CEO and Chairman, Director | 886,598 | $4.67 | $347,883 | 0 | — | plan? |
| Feb 3, 2016 DFMForm 4 → | Feb 4, 4:35 pm EST | Michael R KramerChief Financial Officer | 154,373 | $3.91 | $116,508 | 0 | — | plan? |
| Feb 3, 2016 DForm 4 → | Feb 4, 1:26 pm EST | James Paul ScopaDirector | 1,776,692 | — | — | 0 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2016 MForm 4 → | Feb 4, 4:45 pm EST | Robert ThomasDirector | 16,523 | — | — | 0 | — | |
| Feb 3, 2016 MForm 4 → | Feb 4, 4:43 pm EST | Daniel Jeffrey MooreDirector | 15,661 | — | — | 0 | — | |
| Feb 3, 2016 MForm 4 → | Feb 4, 4:42 pm EST | Shari L O'QuinnVP Clinical/Regulatory Affairs | 51,238 | — | — | 0 | — | |
| Feb 3, 2016 MForm 4 → | Feb 4, 4:41 pm EST | Vivek K JayaramanVP Global Sales and Marketing | 60,178 | — | — | 0 | — | |
| Feb 3, 2016 MForm 4 → | Feb 4, 4:40 pm EST | Kimberley A. EltingVP, Gen. Counsel and Secretary | 76,621 | — | — | 0 | — | |
| Feb 3, 2016 MForm 4 → | Feb 4, 4:37 pm EST | Michael V. ChobotovChief Technology Officer | 34,537 | — | — | 0 | — | |
| Feb 3, 2016 MForm 4 → | Feb 4, 4:36 pm EST | Christopher G. ChavezPresident, CEO and Chairman, Director | 113,323 | — | — | 0 | — | |
| Feb 3, 2016 MForm 4 → | Feb 4, 4:35 pm EST | Michael R KramerChief Financial Officer | 31,032 | — | — | 0 | — | |
| May 22, 2015 AForm 4 → | May 27, 6:19 pm EDT | Jason Raleigh NunnDirector | 10,000 | — | — | 10,000 | — | |
| May 22, 2015 AForm 4 → | May 27, 6:18 pm EDT | Ryan D DrantDirector, 10% Owner | 10,000 | — | — | 10,000 | — | |
| May 22, 2015 AForm 4 → | May 27, 6:13 pm EDT | Daniel Jeffrey MooreDirector | 10,000 | — | — | 10,000 | — | |
| May 22, 2015 AForm 4 → | May 27, 6:12 pm EDT | James Paul ScopaDirector | 10,000 | — | — | 10,000 | — | |
| May 22, 2015 AForm 4 → | May 27, 6:12 pm EDT | Robert ThomasDirector | 10,000 | — | — | 10,000 | — | |
| May 22, 2015 AForm 4 → | May 27, 6:12 pm EDT | Douglas A RoederDirector, 10% Owner | 10,000 | — | — | 10,000 | — | |
| Mar 2, 2015 AForm 4 → | Mar 4, 8:18 pm EST | Kimberley A. EltingVP, Gen. Counsel and Secretary | 43,400 | — | — | 28,400 | — | |
| Mar 2, 2015 AForm 4 → | Mar 4, 8:17 pm EST | Christopher G. ChavezPresident, CEO and Chairman, Director | 168,703 | — | — | 85,100 | — | |
| Mar 2, 2015 AForm 4 → | Mar 4, 8:17 pm EST | Michael R KramerChief Financial Officer | 43,400 | — | — | 28,400 | — | |
| Mar 2, 2015 AForm 4 → | Mar 4, 8:17 pm EST | Shari L O'QuinnVP Clinical/Regulatory Affairs | 27,100 | — | — | 17,700 | — | |
| Mar 2, 2015 AForm 4 → | Mar 4, 8:17 pm EST | Louis J. MolinariVP Manufacturing Operations | 27,100 | — | — | 17,700 | — | |
| Mar 2, 2015 AForm 4 → | Mar 4, 8:16 pm EST | Robert G WhirleyVP Research and Development | 27,100 | — | — | 17,700 | — | |
| Mar 2, 2015 AForm 4 → | Mar 4, 8:16 pm EST | Michael V. ChobotovChief Technology Officer | 35,800 | — | — | 23,400 | — | |
| Mar 2, 2015 AForm 4 → | Mar 4, 8:16 pm EST | Vivek K JayaramanVP Global Sales and Marketing | 35,800 | — | — | 23,400 | — | |
| Nov 30, 2013 AForm 5/A → | Feb 13, 2015, 4:45 pm EST | Christopher G. ChavezPresident, CEO and Chairman, Director | 198,585 | — | — | 29,720 | — | |
| Nov 29, 2013 AForm 5/A → | Feb 13, 2015, 4:48 pm EST | Kimberley A. EltingVP, Gen. Counsel and Secretary | 18,486 | — | — | 18,486 | — | |
| Nov 29, 2013 AForm 5/A → | Feb 13, 2015, 4:47 pm EST | Louis J. MolinariVP Manufacturing Operations | 13,556 | — | — | 13,556 | — | |
| Nov 29, 2013 AForm 5/A → | Feb 13, 2015, 4:47 pm EST | Shari L O'QuinnVP Clinical/Regulatory Affairs | 18,485 | — | — | 18,485 | — | |
| Nov 29, 2013 AForm 5/A → | Feb 13, 2015, 4:46 pm EST | Vivek K JayaramanVP Global Sales and Marketing | 18,486 | — | — | 18,486 | — | |
| Nov 29, 2013 AForm 5/A → | Feb 13, 2015, 4:46 pm EST | Michael R KramerChief Financial Officer | 32,043 | — | — | 32,043 | — | |
| Nov 29, 2013 AForm 5/A → | Feb 13, 2015, 4:45 pm EST | Michael V. ChobotovChief Technology Officer | 81,683 | — | — | 49,641 | — | |
| Nov 29, 2013 AForm 5/A → | Feb 13, 2015, 4:43 pm EST | Robert G WhirleyVP Research and Development | 13,556 | — | — | 13,556 | — |